About Us
ImmuneSensor Therapeutics is developing novel medicines that target the cGAS (cyclic GMP-AMP synthase) – STING (stimulator of interferon genes) pathway to modulate the innate immune system. Based on groundbreaking discoveries from the lab of Dr. Zhijian “James” Chen, Professor of Molecular Biology at the University of Texas Southwestern Medical Center and an HHMI Investigator, we are developing STING activators to boost anticancer immunity and inhibitors to suppress autoimmunity when it is overactive. We are currently conducting a first-in-human Phase 1 clinical study with our lead asset, a small molecule STING activator to treat solid tumors. Our pipeline includes 2nd-generation STING activators, as well as STING inhibitors for the treatment of autoimmune disease.